Loading company…
Remedicine develops tumor treatment equipment based on irreversible electroporation, including pulsed electric field ablation devices.
Established in 2016 and based in Shanghai, China, Remedicine CO., LTD develops tumor treatment equipment for the irreversible electroporation field. Its products include compound steep pulse treatment equipment, and its pulsed electric field ablation device was approved by the State Drug Administration of China in July 2022. The company has completed three funding rounds as of 2023 and plans to use Series A+ funding to expand products for prostate enlargement, atrial fibrillation and liver cancer.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in